Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) has received a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $32.00.
Several brokerages have recently issued reports on ACRS. BTIG Research reduced their price target on shares of Aclaris Therapeutics from $32.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, March 7th. Cantor Fitzgerald restated an “overweight” rating and set a $38.00 price objective on shares of Aclaris Therapeutics in a research note on Tuesday, February 7th. HC Wainwright cut their price objective on shares of Aclaris Therapeutics from $50.00 to $43.00 and set a “buy” rating on the stock in a research note on Tuesday, March 7th. StockNews.com started coverage on shares of Aclaris Therapeutics in a research note on Thursday, May 18th. They set a “sell” rating on the stock. Finally, The Goldman Sachs Group cut their price objective on shares of Aclaris Therapeutics from $25.00 to $21.00 and set a “buy” rating on the stock in a research note on Tuesday, March 7th.
Aclaris Therapeutics Price Performance
Aclaris Therapeutics stock opened at $8.33 on Friday. The company has a market cap of $588.76 million, a PE ratio of -5.78 and a beta of 0.51. The company has a fifty day moving average price of $8.59 and a two-hundred day moving average price of $12.67. Aclaris Therapeutics has a 12 month low of $5.77 and a 12 month high of $18.96.
Insiders Place Their Bets
In related news, CEO Douglas J. Manion acquired 6,500 shares of the business’s stock in a transaction on Thursday, March 9th. The shares were purchased at an average price of $7.74 per share, for a total transaction of $50,310.00. Following the acquisition, the chief executive officer now owns 6,500 shares in the company, valued at $50,310. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Aclaris Therapeutics news, insider Joseph Monahan sold 14,800 shares of Aclaris Therapeutics stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $12.37, for a total transaction of $183,076.00. Following the transaction, the insider now owns 151,261 shares of the company’s stock, valued at approximately $1,871,098.57. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Douglas J. Manion bought 6,500 shares of the stock in a transaction on Thursday, March 9th. The shares were acquired at an average cost of $7.74 per share, for a total transaction of $50,310.00. Following the purchase, the chief executive officer now owns 6,500 shares in the company, valued at $50,310. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 44,800 shares of company stock worth $554,096. 6.70% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Aclaris Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the business. Great West Life Assurance Co. Can purchased a new position in Aclaris Therapeutics during the 3rd quarter valued at about $31,000. UBS Group AG grew its stake in shares of Aclaris Therapeutics by 41.4% in the 2nd quarter. UBS Group AG now owns 2,406 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 704 shares in the last quarter. Point72 Middle East FZE bought a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at approximately $75,000. Corton Capital Inc. bought a new stake in shares of Aclaris Therapeutics in the 1st quarter valued at approximately $84,000. Finally, State of Wyoming bought a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at approximately $87,000. Hedge funds and other institutional investors own 95.33% of the company’s stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments.
- Get a free copy of the StockNews.com research report on Aclaris Therapeutics (ACRS)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.